UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
|Articles|August 21, 2019
Enable Injections Enter into Development Agreement with Genentech
Author(s)BioPharm International Editors
The companies will work together to produce enFuse, a patient-administered subcutaneous delivery device.
Advertisement
Device manufacturer Enable Injections, Inc. announced it has entered into a development agreement with Genentech for programs using Enable’s enFuse, an investigational wearable infusion device that allows patient-administered subcutaneous delivery of high-volume therapeutics. The collaboration has the potential for multiple molecule development programs incorporating long-term manufacturing and supply arrangements.
According to an Aug. 21, 2019 press release, the device is an on-body drug delivery platform with a drug transfer system compatible with standard syringes or vial container formats. It is designed for subcutaneous administration of large volumes ranging up to 50 mL and has the potential to provide patients and caregivers with an alternative delivery method for subcutaneous administration of parenteral therapies outside of a clinical setting.
“Enable Injections is pleased to partner with Genentech in its focus on delivering patient-focused solutions,” said Michael D. Hooven, Enable Injections founder, president, and CEO, in the press release. “With the enFuse paired to deliver selected subcutaneous therapeutics, it can potentially benefit patients worldwide.”
Source:
Advertisement
Related to this article
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5